Pathogenicity of IgG-Fc desialylation and its association with Th17 cells in an animal model of systemic lupus erythematosus

• Published in: Modern rheumatology 2024-03, Vol.34 (3), p.523-529
• Main Authors: Nishida, Yuri, Shirakashi, Mirei, Hashii, Noritaka, Nakashima, Ran, Nakayama, Yoichi, Katsushima, Masao, Watanabe, Ryu, Onizawa, Hideo, Hiwa, Ryosuke, Tsuji, Hideaki, Kitagori, Koji, Akizuki, Shuji, Onishi, Akira, Murakami, Kosaku, Yoshifuji, Hajime, Tanaka, Masao, Tsuruyama, Tatsuaki, Morinobu, Akio, Hashimoto, Motomu
• Format: Article
• Language: English
• Subjects: Animals; beta-Glucans; Disease Models, Animal; Immunoglobulin G; Lupus Erythematosus, Systemic - genetics; Mice; Th17 Cells; Virulence
• ISSN: 1439-7595; 1439-7609
• DOI: 10.1093/mr/road054

Decreased sialylation of IgG-Fc glycans has been reported in autoimmune diseases, but its role in systemic lupus erythematosus (SLE) is not fully understood. In this study, we examined the pathogenicity of IgG desialylation and its association with Th17 in SLE using an animal model. B6SKG mice, which develop lupus-like systemic autoimmunity due to the ZAP70 mutation, were used to investigate the pathogenicity of IgG desialylation. The proportion of sialylated IgG was compared between B6SKG and wild-type mice with or without β-glucan treatment-induced Th17 expansion. Anti-interleukin (IL)-23 and anti-IL-17 antibodies were used to examine the role of Th17 cells in IgG glycosylation. Activation-induced cytidine deaminase-specific St6gal1 conditionally knockout (cKO) mice were generated to examine the direct effect of IgG desialylation. The proportions of sialylated IgG were similar between B6SKG and wild-type mice in the steady state. However, IgG desialylation was observed after β-glucan-induced Th17 expansion, and nephropathy also worsened in B6SKG mice. Anti-IL-23/17 treatment suppressed IgG desialylation and nephropathy. Glomerular atrophy was observed in the cKO mice, suggesting that IgG desialylation is directly involved in disease exacerbation. IgG desialylation contributes to the progression of nephropathy, which is ameliorated by blocking IL-17A or IL-23 in an SLE mouse model.